GILD
Gilead Sciences

Conference date: October 28, 2014 @ 1:30 PM Pacific Time

Could GlaxoSmithKline Be a Better Investment Than Gilead? [September 17, 2014]
The Solid Gold Wonder Drug [September 2014 Scientific American]
FDA Approves Zydelig (idelalisib) for CLL, FL, and SLL [July 23, 2014 Gilead press release]
Gilead Down on Merck-Idenix Deal, But Little to Fear [June 9, 2014 at Seeking Alpha]


Analyst Conference summaries and reports available:

2014
Gilead GILD analyst conference call Q1 2014
Gilead GILD analyst conference call Q2 2014
Gilead GILD analyst conference call Q3 2014
 
04/22/2014
07/23/2014
10/28/2014
 
Q1 2014
Q2 2014
Q3 2014  
 
2013
Gilead GILD analyst conference call Q1 2013
Gilead GILD analyst conference call Q2 2013
Gilead GILD analyst conference call Q3 2013
Gilead GILD analyst conference call Q4 2013
05/02/2013
07/25/2013
10/29/2013 
02/04/2014 
Q1 2013
Q2 2013
Q3 2013
Q4 2013  
2012
Gilead GILD analyst conference call Q1 2012
Gilead GILD analyst conference call Q2 2012
Gilead GILD analyst conference call Q3 2012
Gilead GILD analyst conference call Q4 2012
04/26/2012
07/26/2012
10/23/2012
02/04/2013
Q1 2012
Q2 2012 
Q3 2012
Q4 2012
2011
Gilead GILD analyst conference call Q1 2011
Gilead GILD analyst conference call Q2 2011
Gilead GILD analyst conference call Q3 2011
Gilead GILD analyst conference call Q4 2011
04/20/2011
 07/26/2011
10/27/2011 
02/02/2012
Q1 2011
 Q2 2011
Q3 2011
Q4 2011
2010
Gilead GILD analyst conference summary Q1 2010
Gilead GILD analyst conference summary Q2 2010
Gilead GILD analyst conference call Q3 2010
Gilead GILD analyst conference call Q4 2010
4/20/2010
07/20/2010 
 10/19/2010
01/25/2011 
Q1 2010
Q2 2010  
Q3 2010  
Q4 2010  
2009
Gilead analyst conference summary Q1 2009
Gilead GILD analyst conference summary Q2 2009
Gilead GILD analyst conference summary Q3 2009
Gilead GILD analyst conference summary Q4 2009
04/21/2009
 07/21/2009
 10/20/2009
 01/26/2010
Q1 2009
Q2 2009  
Q3 2009  
 Q4 2009
2008
Gilead Q1 2008 analyst conference summary
Gilead analyst conference summary Q2 2008
Gilead analyst conference summary q3 2008
Gilead Sciences Q4 2008 analyst conference cummary
04/16/2008
07/17/2008
10/16/2008
01/27/2009
Q1 2008
Q2 2008
Q3 2008
Q4 2008
2007
Gilead Q4 2007 analyst conference summary
Gilead Q3 analyst conference summary
GILD Q2 2007
GILD conference
01/23/2008
10/18/2007
7/19/2007
4/18/2007
Q4 2007
Q3 2007
Q2 2007
Q1 2007

Gilead Sciences Hepatitis C Approval May Be Factored In [July 30, 2013]
Gilead Sciences Pipeline Remains Undervalued [December 3, 2012]
Gilead Sciences, Biogen Idec, and Celgene [August 13, 2012]
Gilead Sciences Looks for Hepatitis C Cure [April 29, 2012]
Gilead Sciences Readies Pipeline [July 27, 2011]
Gilead Sciences, Antivirals, and Tamiflu [January 26, 2011]
Gilead Sciences Rebuilds Pipeline Optimism [October 24, 2010]
Gilead Sciences (GILD) Q2 Outlook [July 6, 2009]
Gilead (GILD) Thrives Despite Downturn [October 21, 2008]
Aztreonam Lysine Rejected by FDA [September 20, 2008]
Gilead Should Rise on Penetration, Viread [September 10, 2008]
Gilead Preps for Atripla in Europe [January 24, 2008]
Choosing a Biotech Stock 2: Gilead [September 10, 2007]

Gilead is a biotechnology pharmaceutical company; products include Atripla, Truvada, and Sovaldi. So far it has specialized in anti-viral agents for HIV, Hepatitis B, and Hepatitis C as well as cancer and cardiovascular therapies.

I own this stock

Gilead Sciences Web site:

Gilead Sciences main page
Gilead Sciences investor page

Disclaimer: Our analyst summaries may include both our condensations of statements made by company representatives and our own analysis. They are not covered by any warranty. We cannot guarantee anything said by company representatives is true. We try not to make errors, but its possible. Before making or terminating an investment you should always verify any factual basis of your decision.